Mostrar el registro sencillo del ítem
dc.contributor.author | Santos, Arnoldo | |
dc.contributor.author | Martínez-Milla, Juan | |
dc.contributor.author | Pérez-Calvo, César | |
dc.contributor.author | Ibáñez, Borja | |
dc.date.accessioned | 2023-04-11T14:51:50Z | |
dc.date.available | 2023-04-11T14:51:50Z | |
dc.date.issued | 2022-01-04 | |
dc.identifier.citation | J Am Coll Cardiol. 2022 Jan 4;79(1):e13-e14 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/15766 | |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.mesh | COVID-19 | es_ES |
dc.subject.mesh | Metoprolol | es_ES |
dc.subject.mesh | Administration, Intravenous | es_ES |
dc.subject.mesh | Adrenergic beta-1 Receptor Antagonists | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | SARS-CoV-2 | es_ES |
dc.title | Reply: Biological Plausibility Behind the Benefits of Intravenous Metoprolol in Severe COVID-19. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 34991793 | es_ES |
dc.format.volume | 79 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | e13 | es_ES |
dc.identifier.doi | 10.1016/j.jacc.2021.10.030 | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1558-3597 | es_ES |
dc.relation.publisherversion | 10.1016/j.jacc.2021.10.030 | es_ES |
dc.identifier.journal | Journal of the American College of Cardiology | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovascular | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.rights.accessRights | open access | es_ES |